English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Summary  There is an urgent need to provide effective anti‐HIV microbicides to resource‐poor areas worldwide. Some of the most promising microbicide candidates are biotherapeutics targeting viral entry. To provide biotherapeutics to poorer areas, it is vital to reduce the cost. Here, we report the production of biologically active recombinant cyanovirin‐N ( rCV ‐N), an antiviral protein, in genetically engineered soya bean seeds. Pure, biologically active  rCV ‐N was isolated with a yield of 350 μg/g of dry seed weight. The observed amino acid sequence of  rCV ‐N matched the expected sequence of native CV‐N, as did the mass of  rCV ‐N (11 009 Da). Purified  rCV ‐N from soya is active in anti‐HIV assays with an EC 50  of 0.82–2.7 nM (compared to 0.45–1.8 nM for  E. coli ‐produced CV‐N). Standard industrial processing of soya bean seeds to harvest soya bean oil does not diminish the antiviral activity of recovered  rCV ‐N, allowing the use of industrial soya bean processing to generate both soya bean oil and a recombinant protein for anti‐HIV microbicide development.

Engineering soya bean seeds as a scalable platform to produce cyanovirin‐N, a non‐ ARV microbicide against HIV